{
  "guideline": {
    "id": "PA166104831",
    "name": "Annotation of FDA Label for irinotecan and UGT1A1",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 30,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104831",
    "relatedChemicals": [
      {
        "id": "PA450085",
        "name": "irinotecan",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA420",
        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
        "symbol": "UGT1A1"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312562",
      "name": "Recommendation Annotation PA166312562",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450085",
          "name": "irinotecan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452217281,
        "html": "<p>The CAMPTOSAR [irinotecan] label states &quot;Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR [irinotecan] treatment...When administered in combination with other agents or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele. However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment.&quot;<br />\nThe ONIVYDE [irinotecan] label states &quot;The recommended dose of ONIVYDE [irinotecan] is 70 mg/m<sup>2</sup> administered by intravenous infusion over 90 minutes every 2 weeks...The recommended starting dose of ONIVYDE in patients known to be homozygous for the UGT1A1*28 allele is 50 mg/m<sup>2</sup> administered by intravenous infusion over 90 minutes. Increase the dose of ONIVYDE to 70 mg/m<sup>2</sup> as tolerated in subsequent cycles.&quot;<br />\nSee labels for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "UGT1A1": {
          "*28": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Camptosar (irinotecan hydrochloride), NDA020571, Pharmacia and Upjohn Company LLC",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020571"
    }
  ],
  "version": "2024-03-08-14-34"
}